The effect of compound "Ma-ol-asal" on treatment of the pediatric asthma

The effect of compound "Ma-ol-asal" on clinical manifestation of the pediatric asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015083123834N1

Enrollment

Registered

2015-09-16

Start date

2015-09-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

Intervention 1: Intervention group: Fluticasone spray 50 mcg 2 puffs every 12 hours and salbutamol that was used in cases of exacerbated their symptoms. In addition to the aforementioned treatment,

Treatment - Drugs

Intervention group: Fluticasone spray 50 mcg 2 puffs every 12 hours and salbutamol that was used in cases of exacerbated their symptoms. In addition to the aforementioned treatment, the experimental

Control group: Fluticasone spray 50 mcg 2 puffs every 12 hours and salbutamol that was used in cases of exacerbated their symptoms

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with asthma aged 6-16 years old that referred to the pulmonary clinic of the Mofid Children's Hospital, Tehran, Iran; patients who are willing and consent to participate in the study. Exclusion criteria: Patients under 6 and over 16 yearsold; patients with modprate asthma; patients with severe asthma; patients requiring hospitalization and patients who have attack; patients with underlying diseases such as CF, Bronchopulmonary dysplasia, heart failure, bronchotracheomalacia, GERD, bronchiectasis, Pulmonary embolism and sarcoidosis; patients who are taking medications such as aspirin, beta blocker and NSAID's; patients who become affected to other acute disease during the study; patients who are allergic to any components of compound "Ma-ol-asal" and request and patients who have decision to excluded from the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Breathlessness. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Asthma Control Questionnaire.;Cough. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Asthma Control Questionnaire.;Wheez. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Asthma Control Questionnaire.;FEV1. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention. Method of measurement: Spirometry.;FVC. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Spirometry.;FEF25-75. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Spirometry.;FEV1/ FVC. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Spirometry.;Allergic rhinitis. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Examination.	—

Measure

Time frame

Breathlessness. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Asthma Control Questionnaire.;Cough. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Asthma Control Questionnaire.;Wheez. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Asthma Control Questionnaire.;FEV1. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention. Method of measurement: Spirometry.;FVC. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Spirometry.;FEF25-75. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Spirometry.;FEV1/ FVC. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Spirometry.;Allergic rhinitis. Timepoint: Before the intervention, and at the end of eghth week (end of the intervention). Method of measurement: Examination.

—

Secondary

Measure	Time frame
BMI. Timepoint: Before the intervention and after the intervention. Method of measurement: kg/m2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahpar Kaveh Bagh Bahadorani

Shahid Beheshti University of Medical Sciences, School of Traditional Medicine

skaveh83@yahoo.com+98 21 8877 6327

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026